Novo Nordisk entered 2026 with a headline achievement: the launch of the first GLP-1 pill for obesity, and early patient uptake that management says is already ahead of prior GLP-1 injection rollouts.
Then the year immediately turned into a test of control.
In a short stretch, Novo delivered a 2026 outlook that disappointed investors, sued Hims & Hers for alleged patent infringement tied to compounded semaglutide, and received an FDA warning over what the agency described as misleading claims in advertising. The stock’s trading range and daily swings underline what the market is actually pricing: not whether obesity drugs are big, but whether Novo can defend its position inside a market that is becoming less forgiving by the month.
One blunt sentence.
This is no longer a growth story. It’s a governance story.
Start with the guidance. Eli Lilly guided to 2026 sales growth of 25%. Novo’s forecast allows for sales and profits to decline by as much as 13% this year. That spread is the entire emotional center of the piece. It’s not just a numbers contrast; it’s a credibility contrast. Novo is effectively telling investors that it sees the headwinds as visible and immediate enough to dominate near-term results, even as it claims patient volumes will be higher than ever and production will exceed prior years. Those statements can coexist, but they are not emotionally compatible for a market that has been trained to treat GLP-1 leaders as compounding machines.
“This wasn’t about demand. It was about the price and the leakage.”
The company’s CEO, Mike Doustdar, is positioned here as a reset figure. He took over in August after the former CEO was ousted over misjudging the U.S. market and challenges there. His plan, as described, is not subtle: crack down on compounded “copycats,” sustain demand for the newly launched pill, build U.S. prescriptions, and bring next-generation treatments to market. The agenda reads like a list of problems that would each be a full-year headache on their own. That’s the point. This is a “show me” year because Novo is being asked to execute on multiple fronts while the market’s tolerance for excuses collapses.
The compounding issue is the hinge. Novo estimates 1.5 million Americans are currently taking compounded versions of semaglutide offered by Hims & Hers, wellness clinics, and compounding pharmacies. The article frames compounding as a key reason for slowing sales growth, and it treats the continuation of mass marketing after branded semaglutide injections are no longer in short supply as the core controversy. Novo’s posture is carefully worded: it says its opposition is not about medically necessary compounding for individual cases; it is about mass compounding and mass marketing that, in Novo’s view, outlived the original shortage rationale.
The pressure here is not simply lost sales. It is a distortion of the market’s feedback loop. When millions of patients can access a cheaper substitute that leans on a regulatory loophole and direct-to-consumer marketing, the branded manufacturer loses control over price signaling, brand trust, and the clean relationship between prescription demand and reported revenue. It turns what should be an orderly category expansion into a messy, reputationally charged price war where the incumbent is forced to argue about legitimacy instead of outcomes.
This is why the lawsuit matters. Novo sued Hims over compounded versions of injectable and oral semaglutide, adding to more than 130 lawsuits it has filed against pharmacies, wellness clinics, and other firms marketing those copycats. The number is worth sitting with. It implies the company has decided that legal enforcement is not a side project; it is now a structural operating function. That carries costs and risks, but it also reveals how Novo sees the threat: not as fringe, but as systemic.
Here is the long paragraph that matters, because it ties the entire year together. Novo’s strategic puzzle in this article is that its product innovation is landing into a market that is simultaneously getting cheaper, more contested, and more politically sensitive. The Wegovy pill launch is described as explosive, and management claims that 246,000 patients are currently on the pill and that it is outpacing early rollouts of existing GLP-1 injections. That suggests the oral format is pulling in new patients, which Novo reinforces by noting that 88% of pill users are on the lowest starter dose, signaling many are early in treatment and may have been waiting for an oral option. At the same time, the company is trying to choke off a large shadow market of compounded semaglutide that it says began due to shortages but continued despite shortages easing. The article adds a political layer: removing cheaper drugs from the market may not be an easy sell while the Trump administration has made lower drug prices a priority, yet the “last straw” described by an analyst was the attempted move into a compounded version of the newly launched pill within weeks of launch. The FDA then announced a broader crackdown on compounding, and the agency said it referred Hims to the Department of Justice over potential violations. Novo’s guidance, however, likely does not include any reduction in compounded drug volumes because the FDA’s decisive steps came after the guidance was released. So the year becomes a race between three clocks: Novo’s ability to scale real prescriptions and volumes, the speed of price erosion from “most favored nation” deals and other factors, and the enforcement timeline that could shrink the compounded market. If the crackdown tightens quickly, Novo gets back some control and potentially some share. If it doesn’t, Novo is forced to compete in a market where the branded leader is treated like a premium option while the cheapest, most aggressively marketed alternative keeps absorbing the marginal patient.
“This is what it looks like when a category matures before the leader is ready for it.”
The market share section removes any remaining comfort. Weight loss accounted for more than half of Novo’s sales in 2025. That makes U.S. market share not a vanity metric but a financial spine. The article cites estimates that Lilly has around 60% of the branded GLP-1 market globally while Novo has about 39%. In the U.S., Novo estimates that between 7 and 8 out of 10 patients go to Lilly. There is also mention of a “preference share” gap for Wegovy versus Lilly’s injections, with Zepbound described as showing more pronounced weight loss and becoming preferred among patients and prescribers despite launching years after Novo’s drugs.
This is the part that quietly changes the framing from “Novo versus copycats” to “Novo versus time.” Even if the compounding issue gets controlled, Novo is still fighting a branded market where the center of gravity has shifted. The compounded market adds insult because the share of copycats for Novo’s molecule outweighs that of Lilly’s, a curious asymmetry that even analysts say they don’t fully understand. But the takeaway is simple: Novo is being attacked where it is most exposed. The copycat market is disproportionately semaglutide. The branded preference is disproportionately Lilly. Novo is squeezed from both ends.
The pill is Novo’s attempted escape hatch. It is being used to reclaim first-mover advantage in a format patients may prefer, and to reach new patients. Novo is also “putting a lot of muscle behind the marketing,” including a reinvigorated direct-to-consumer channel that it was late to adopt. The article frames that as paying dividends.
But the window is not open forever. Lilly is expected to launch its rival weight loss pill, orforglipron, in the second quarter of 2026. Investors are watching it closely, with the explicit reminder that Novo has lost first-mover advantage before. The marketing battle is forecast in plain terms: Lilly will likely argue Novo’s pill is inconvenient because of food restrictions, while Novo insists those requirements won’t hinder uptake. An analyst notes those restrictions could help Lilly’s pill generate greater global sales.
The source includes a clinical-trial-based efficacy comparison presented by Doustdar: Wegovy pill showed around 16.6% weight loss versus roughly 12.4% for Lilly’s oral drug, and he frames that as a roughly 40% difference. He calls it a main selling point. That claim is powerful in marketing terms, but it also sets a trap: when you anchor your commercial narrative to a numeric edge, you raise the market’s expectation that the edge will translate into real-world preference and share quickly.
Pricing headwinds are the other structural pressure, and they cut across everything. The GLP-1 market is described as facing broad price erosion following “most favored nation” deals with the Trump administration. It is unclear how much of the price decline can be offset by volume increases. Doustdar acknowledges the math problem: catching up to a price decrease takes time. Analysts believe Novo is being intentionally cautious, baking in high-visibility negatives like pricing declines, generics in Canada and some markets, and restrictions on Medicaid for some drugs, while not counting on lower-visibility positives such as the compounded market shrinking.
“This is a management team trying to stop promising and start surviving.”
The Medicare angle sits in the background as a potential release valve. Novo anticipates Medicare coverage for weight loss treatments later this year, and Doustdar describes it as a 15 million-patient opportunity inside a 67 million-person Medicare population, with access expected to open gradually. That could expand the addressable market and add volume, but the article treats price sensitivity as a major unknown. More patients is not the same as more profit when prices are coming down and the market is saturated with alternatives.
Finally, there is the pipeline. Novo is waiting for FDA approval of a higher 7.2mg dose of Wegovy, which Doustdar says helps patients lose around 21% and would be on par with the highest dose of Zepbound. Novo also expects its next-generation treatment CagriSema to enter the market later this year. The company defended its trial results after investors were disappointed that the weight loss came in around 23% rather than the expected 25%. Doustdar argues the stock market penalized the company harshly and says the drug would be among the best products if available today. He points to upcoming Phase 3 trials, including one comparing CagriSema against Zepbound.
The pipeline section is not just R&D optimism. It is the implicit admission that defending share may require changing the product conversation. If Zepbound is entrenched as best-in-class in injectables, the only way to break that entrenchment is either a comparable efficacy profile, a format shift that patients prefer, or a distribution and access advantage. Novo is trying to do all three at once: push an oral product, raise the injectable dose, and bring a next-gen combination to market. That is bold, but it is also what you do when you can’t afford to lose.
So what actually matters after reading?
Novo’s year is “defining” because the company is being tested on whether it can regain control of the category’s plumbing: pricing, access, enforcement, marketing, and product sequencing. The science is not the immediate question in this piece. The operating environment is.
And the market is no longer grading on effort.
By Nassim Shadid
